INTRODUCTION AND OBJECTIVES:
Since benign prostatic hyperplasia (BPH) is a chronic and refractory disease and medical therapy became a standard treatment for most BPH patients with mild to moderate lower urinary tract symptoms, adherence to and persistence with therapy are considered important factors for the success of the treatment. Monotherapy using alpha-adrenergic antagonist constitutes the largest portion of medical therapy for BPH. Therefore, we aimed to assess and predict patient-reported goal achievement after treatment of BPH patients with tamsulosin.
METHODS: From November 2013 to October 2015, 272 patients initially diagnosed with BPH were prospectively enrolled in nine different centers. Before the treatment, subjective final goals were recorded by all patients. Every four weeks, the treatment outcomes were evaluated using international prostate symptom score (IPSS) and uroflowmetry. Patient-reported goal achievements were assessed after 12 weeks of treatment and risk factors for lower scores of goal achievement were assessed using logistic regression analysis.
RESULTS: Of the enrolled patients, 179 patients completed the study and 42 patients set multiple goals (32 patients with 2 goals, 9 patients with 3 goals and 1 patient with 4 goals). The pretreatment patients' goals included the nocturia improvement (n¼63), weak urine stream improvement (n¼52), frequency improvement (n¼34), residual urine sense improvement (n¼27), hesitancy improvement (n¼22), well voiding (n¼21), urgency improvement (n¼11), and voiding-related discomfort improvement (n¼2). Of the 179 patients, 129 patients (72.1%) reported that they achieved their primary goals after three months of medical therapy. Logistic regression analysis revealed that pretreatment quality of life (OR¼8.621, 95% CI: 2.154-9.834), and improvement of quality of life (OR¼6.740, 95% CI: 1.908-11.490) were independent predictors of patient-reported goal achievement after tamsulosin monotherapy.
CONCLUSIONS: Overall patient-reported goal achievement after medical therapy for BPH was high, and the scores of pretreatment quality of life and improvement of quality of life can be important factors to predict the achievement of treatment goals.
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MP09-12 DECISION-MAKING IN MEN CONSIDERING USE OF NON-PRESCRIPTION TAMSULOSIN FOR LOWER URINARY TRACT SYMPTOMS
INTRODUCTION AND OBJECTIVES: Tamsulosin is undergoing evaluation for non-prescription (OTC) use in men with lower urinary tract symptoms (LUTS). We aimed to assess appropriate decisionmaking and LUTS in men choosing to use tamsulosin in a simulated OTC setting.
METHODS: Adult men not taking a prescription medication for benign prostatic hyperplasia (BPH) were shown a mock-up of the drug packaging and asked if the medication would be appropriate for their personal use. Criteria for appropriate "self-selection" included: 2 or more specified LUTS for at least 3 months, absence of any 00 Do Not Use 00 warning symptoms, and no allergy to sulfa or tamsulosin. Compliance with 00 Ask a Doctor Before Use 00 conditional warnings was assessed in a separate analysis. Three urologists reviewed the data of men reporting the product to be appropriate for their use who did not meet appropriate self-selection criteria. CONCLUSIONS: Men self-selecting use of tamsulosin are characterized by chronic LUTS with a voiding component, suggesting potential benefit from the medication. The decision to use tamsulosin based on indications and warnings was appropriate for most men, including those with low health literacy, which may mitigate risks associated with self-directed use.
Source of Funding: This study was funded by BoehringerIngelheim. The authors received no direct compensation related to the development of this abstract. AV and JW are employees of the sponsor.
MP09-13 CLINICAL EFFICACY AND SAFETY OF FULL DOSE ANTIMUSCARINIC AGENT TREATMENT ON UNSATISFACTORY IMPROVEMENT OF SYMPTOMS AFTER LOW DOSE ANTIMUSCARINIC TREATMENT IN MALE PATIENTS WITH OVERACTIVE BLADDER: A RETROSPECTIVE MULTICENTER STUDY
Myungsun Shim*, Woo Jin Bang, Cheol Young Oh, Yong Seong Lee, Jin Seon Cho, Anyang-si, Gyeonggi-do, Korea, Republic of
INTRODUCTION AND OBJECTIVES:
This study aimed to analyze the efficacy and safety of full dose antimuscarinic treatment on male patients with overactive bladder (OAB) symptoms who showed unsatisfactory improvements after low dose antimuscarinic treatments.
METHODS: We retrospectively reviewed the data of 567male patients aged 40 or older with OAB symptoms between January 2013 and June 2015. All patients were treated with low dose antimuscarinics at least for 4 weeks and showed unsatisfactory symptom improvements and therefore changed to full dose antimuscarinics using 10 mg of solifenacin for more than 12 weeks. International Prostate Symptom Score (IPSS) and Overactive Bladder Symptom Score (OABSS) at baseline (V0), 4 weeks (V1), and 12 weeks (V2) were analyzed. Safety of treatment was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. RESULTS: Among the total patients, one showed acute urinary retention and was excluded, leaving 566 patients in the analysis. Median age, body mass index, and prostate-specific antigen were 69.0 years, 24.2 kg/m2, and 1.24 ng/dL respectively. Mean value of total IPSS and OABSS scores significantly decreased from V0 to V2 (16.73 to 13.69, and 7.33 to 5.34, respectively, all p < 0.001). All scores of each questionnaires demonstrated significant decrease except for IPSS questionnaires number 3 and 6. Four and nine patients complained constipation and thirst respectively, and all adverse effects were graded 2 or below.
CONCLUSIONS: Full dose antimuscarinic therapy using solilfenacin 5mg may be safe and effective treatment for those patients who have OAB symptoms refractory to low dose antimuscarinic therapy.
e104
THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 
